YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

MyoKardia Gains Venture Funds to Investigate Drugs for Genetic Heart Defects

September 21, 2012 | Third Rock Ventures is investing $38 million in a startup that is targeting the genetic causes of heart problems. MyoKardia will set up shop in San Francisco, and will be led by Third Rock venture partner Charles Homcy and a team of top academic scientists who study the genetics of cardiovascular disease and muscle biology. Xconomy
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.